Iovance Biotherapeutics (IOVA) Stock Statistics & Valuation Metrics

Iovance Biotherapeutics has a market cap or net worth of $1.15B. The enterprise value is $1.99B.

Iovance Biotherapeutics has 327,876,700 shares outstanding. The number of shares has decreased by -2.65% in one year.

Iovance Biotherapeutics’s return on equity (ROE) is -0.52 and return on invested capital (ROIC) is -48.98%.

The current PE Ratio of Iovance Biotherapeutics is -5.76. Iovance Biotherapeutics’s PEG ratio is 0.18.

In the last 12 months, Iovance Biotherapeutics had revenue of 164.07M and earned -372.18M in profits. Earnings per share was -1.28.

In the last 12 months, operating cash flow was -352.98M and capital expenditures -11.07M, giving a free cash flow of -364.05M billion.

Iovance Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Iovance Biotherapeutics upcoming earnings date is May 13, 2025, TBA Not Confirmed.

Iovance Biotherapeutics as a current ratio of 3.74, with Debt / Equity ratio of 8.20%

In the past 12 months, Iovance Biotherapeutics has paid -2.83M in taxes.

Iovance Biotherapeutics EV to EBITDA ratio is -5.28, with an EV/FCF ratio of -5.73.

Iovance Biotherapeutics has $323.78M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$265.52M billion.

Gross margin is 17.93%, with operating margin of -240.92%, and net profit margin of -226.84%.

The average price target for Iovance Biotherapeutics is $18.17, which is 11.43% higher than the current price. The consensus rating is Strong Buy